Gilead Sciences, Inc. (GILD)
| Previous Close | 83.90 |
| Open | 83.26 |
| Bid | 83.33 x 300 |
| Ask | 83.47 x 300 |
| Day's Range | 82.75 - 83.61 |
| 52 Week Range | 62.07 - 87.87 |
| Volume | |
| Avg. Volume | 6,774,553 |
| Market Cap | 103.826B |
| Beta (5Y Monthly) | 0.20 |
| PE Ratio (TTM) | 101.70 |
| EPS (TTM) | 0.82 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | 3.08 (3.67%) |
| Ex-Dividend Date | Sept 13, 2024 |
| 1y Target Est | 82.33 |
ZacksGilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Simply Wall St.High Growth Tech Stocks To Watch This September 2024
As global markets rebound from recent sell-offs, with growth stocks notably outpacing value shares, the technology sector has shown remarkable resilience and potential. With economic indicators such as core inflation slightly higher than expected and Treasury yields reaching year-to-date lows, investors are keenly watching high-growth tech stocks that can capitalize on these dynamic market conditions. In this context, a good stock typically demonstrates strong fundamentals, innovative...
ACCESSWIREWorking to Build Next-Generation Cancer Therapies
NORTHAMPTON, MA / ACCESSWIRE / September 18, 2024 / Gilead Sciences Jackson Egen learned the value of basic lab research as a graduate student at UC Berkeley in the 90s while working under the direction of renowned immunologist James Allison. "Jim ...
